预约演示
更新于：2025-05-16
Gemcitabine
吉西他滨
更新于：2025-05-16
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期- |
最高研发阶段(中国)无进展 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C9H11F2N3O4 |
InChIKeySDUQYLNIPVEERB-QPPQHZFASA-N |
CAS号95058-81-4 |
关联
1,081
项与 吉西他滨 相关的临床试验NCT06364904
A Multicenter, III Stage, Randomized Controlled Trail on the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib in Untreated Unresectable and Metastatic Urothelial Carcinoma.
NCT06622057
Phase III, Randomized, Double-blind Study of Combination Therapy With D07001-Softgel Capsules and Capecitabine vs Placebo and Capecitabine in Patients With Advanced BTC After Failed on Gemcitabine, Platin, and FOLFOX or Irinotecan Regimens
NCT05700448
A Phase III, Randomized, Double-Blind, Multicenter Study of Sugemalimab (CS1001) Plus PGemOx Regimen Versus Placebo Plus PGemOx for Subjects With Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL)
100 项与 吉西他滨 相关的临床结果
登录后查看更多信息
100 项与 吉西他滨 相关的转化医学
登录后查看更多信息
100 项与 吉西他滨 相关的专利（医药）
登录后查看更多信息
29,674
项与 吉西他滨 相关的文献（医药）2025-12-31Molecular & Cellular Oncology
CHK1 inhibition overcomes gemcitabine resistance in non-small cell lung cancer cell A549
Article
作者: Ma, Xuan ; Liang, Ai-Ling ; Fu, Tian ; Wang, Wen-Xuan ; Ke, Zhi-Yin ; Wang, Xue-Chun ; Liu, Yong-Jun ; Yin, Hai-Han
The purpose of the study is mainly to investigate anti proliferation of non-small cell lung cancer A549 cells and its mechanism by inhibition of CHK1 expression combined with gemcitabine. The mRNA and protein levels of genes were analyzed by RT-qPCR and Western blot, respectively. Cell viability was detected by CCK-8 assay and clone formation assay. The detection of the cell cycle was used by Annexin V/7-amino-actinomycin D apoptosis detection kit. Analysis of DNA damage was done by immunofluorescence and alkaline comet assay. The results showed that inhibition of CHK1 and gemcitabine combination significantly reduced the proliferation ability of the two cell lines. We also revealed the degradation of full-length PARP and reduced Bcl-2/Bax ratio on increased apoptosis. Inhibition of CHK1 expression leads to DNA damage, induces phosphorylation of γ-H2AX, and affects the repair of homologous recombination ability through Rad51. Mechanistically, gemcitabine increased phosphorylation-ATR and phosphorylation-CHK1, indicating activation of the DNA repair system and ATR-CHK1-CDC25A pathway. Inhibition of CHK1 resulted in increased synthesis of CDK2/Cyclin A2 and CDK2/Cyclin E1 complexes, and more cells entered the subsequent cell cycle, leading to S phase arrest and mitotic catastrophe. We identified inhibition of CHK1 as a potential treatment for NSCLC and confirmed that inhibition of this kinase could overcome acquired gemcitabine resistance.
2025-12-31JOURNAL OF MEDICAL ECONOMICS
Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States
Article
作者: Li, Jia ; Mahmoudjafari, Zahra ; Masaquel, Anthony ; Parisé, Hélène ; Bercaw, Eric ; Bognar, Katalin ; Wang, Si-Tien
BACKGROUND:
Glofitamab is a T-cell engaging bispecific monoclonal antibody that was granted accelerated approval from the United States Food and Drug Administration for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after ≥2 lines of systemic therapy (3L+).
METHODS:
A budget impact model was developed for a hypothetical blended commercial/Medicare health plan with 1,000,000 members. Comparators were axicabtagene ciloleucel (Axi-cel), lisocabtagene maraleucel (Liso-cel), tisagenlecleucel (Tisa-cel), loncastuximab tesirine, polatuzumab vedotin + bendamustine + rituximab, rituximab + gemcitabine + oxaliplatin, tafasitamab + lenalidomide, and epcoritamab (Epcor). Total costs included those for drugs, wastage, administration, grade ≥3 adverse reactions, and all-grade cytokine release syndrome) and routine care. Market shares were based on internal projections and expert opinions. Total and per-member per-month (PMPM) net budget impacts over 3 years were calculated.
RESULTS:
Approximately nine patients were projected to be eligible for 3L + DLBCL treatment in a health plan of 1,000,000 members. The introduction of glofitamab as a treatment option resulted in estimated total and PMPM cost savings of $728,697 and -$0.0202, respectively, over 3 years. Costs were reduced across all cost categories but particularly in drug costs. Among the newer therapies, total 3-year cost per treated patient was lowest for glofitamab: $226,658 versus Tisa-cel = $564,113; Axi-cel = $540,002; Liso-cel = $516,272; and Epcor = $335,293. Across all sensitivity analyses, the inclusion of glofitamab had minimal PMPM budget impact, ranging from -$0.0256 to -$0.0108.
CONCLUSIONS:
With the lowest 3-year total cost per treated patient among the newer therapies, glofitamab being an available option in the 3L + DLBCL market is estimated to save a hypothetical 1,000,000-member health plan $728,697 in cumulative total costs and $0.0202 in PMPM costs over 3 years.
2025-12-01Journal of Gastrointestinal Cancer
Impact of Retroperitoneal Lymphadenopathy (RPLN) on the Outcomes of Locally Advanced Gall Bladder Cancer (GBC) Following Chemotherapy (CT) or Chemotherapy Followed by Consolidation Chemoradiotherapy (CTRT)
Article
作者: Naik, Nagendra ; Priyanka, Parul ; Agrawal, Sushma
INTRODUCTION:
Retroperitoneal lymphadenopathy is considered a metastatic disease in GBC; however, some surgical series of radical surgery with enlarged RPLN who underwent RPLN dissection have shown results marginally inferior to those without enlarged RPLN. Radiological RPLN comprises a major proportion of advanced non-metastatic GBC. There is dilemma in the intent of treatment to be offered in such cases. We are reporting our series of outcome of GBC with RPLN treated with first-line CT followed by consolidation CTRT.
MATERIALS AND METHODS:
Non-metastatic locally advanced GBC with good performance status (KPS ≥ 80) were initiated on first-line CT (cisplatin-gemcitabine), and thereafter, responders were evaluated by CECT-angiography and PET-CT scan for resectability. If found unresectable, they were offered consolidation CTRT to a dose of 45 Gy by conventional fractionation (3D-CRT technique) along with concurrent capecitabine at 1250 mg/m2 to GBC and regional lymphatics including RPLN. Thereafter, boost dose of 9 Gy/5# was given to GBC only. Response assessment was done using CECT abdomen by RECIST criteria v 1.1. Outcomes (overall survival) of the two groups (RPLN vs non-RPLN) were computed with Kaplan-Meier survival curves and chi-square tests using SPSS v 20.
RESULTS:
Among 189 patients of advanced non-metastatic GBC recruited from 2011 to 2022, 80 had RPLN. The demographic features of both groups were comparable. Overall, 68% of the patients were women, 30% underwent upfront stenting for obstructive jaundice, and 90% had T3 and T4 disease. Only 10% had undergone upfront laparoscopic staging and had pathologically proven RPLN. Forty percent of the patients received four cycles of CT only and 50% of the patients received six cycles or more and 33% received CTRT. By RECIST criteria, 10% vs 16% achieved complete response (CR), 39% vs 41% achieved partial response (PR), 16% vs 15% achieved stable disease (SD), 2.7% vs 6% had disease progression (PD), and 14.5% vs 3.7% were non-evaluable in non-RPLN group vs RPLN group, respectively. 12% vs 6% could undergo radical surgery in non-RPLN group vs RPLN group (p = 0.03). The median OS was 9 months (95% CI 7.6-10.3 months) vs 10 months (95% CI 8-9.8 months) (p = NS) in non-RPLN group vs RPLN group, respectively. In those who received CT only, the median OS was 7 months vs 8 months, while in those who received CT followed by CTRT, the median OS was 14 months vs 13 months (p = 0.65) in non-RPLN group vs RPLN group, respectively.
CONCLUSIONS:
Based on this analysis, we conclude that RPLN constitutes a major proportion of advanced non-metastatic GBC and has outcomes similar to those without RPLN if treated with radical intent. RPLN should not be considered a metastatic disease and should be treated with radical intent.
1,896
项与 吉西他滨 相关的新闻（医药）2025-05-16
·九洲药业
临床3期免疫疗法临床结果临床成功引进/卖出
2025-05-16
·抗体圈
细胞疗法抗体药物偶联物临床结果上市批准
2025-05-15
·癌度
临床结果临床3期优先审批抗体药物偶联物突破性疗法
100 项与 吉西他滨 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胰腺癌 | 临床3期 | - | 2023-06-01 | |
| 转移性胰腺导管腺癌 | 临床3期 | 澳大利亚 | 2022-08-04 | |
| 局部晚期胰腺腺癌 | 临床3期 | 美国 | 2018-03-12 | |
| 局部晚期胰腺腺癌 | 临床3期 | 比利时 | 2018-03-12 | |
| 晚期鳞状细胞肺癌 | 临床3期 | 美国 | 2010-03-01 | |
| 晚期鳞状细胞肺癌 | 临床3期 | 比利时 | 2010-03-01 | |
| 晚期鳞状细胞肺癌 | 临床3期 | 加拿大 | 2010-03-01 | |
| 晚期鳞状细胞肺癌 | 临床3期 | 法国 | 2010-03-01 | |
| 晚期鳞状细胞肺癌 | 临床3期 | 德国 | 2010-03-01 | |
| 晚期鳞状细胞肺癌 | 临床3期 | 匈牙利 | 2010-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 89 | (Chemotherapy (Cisplatin-Gemcitabine)) | 顧糧構醖鬱醖鏇鹹蓋餘(繭蓋製襯壓製蓋製餘願) = 蓋鑰壓獵獵選醖蓋獵鏇 選簾夢遞願夢願遞鏇廠 (廠鏇積蓋艱範壓選積鹹, 鑰艱鬱壓鑰鹽網簾鬱範 ~ 網醖構艱夢鹽齋製積觸) 更多 | - | 2025-05-09 | ||
(Radiation: SIRT + Chemotherapy (Cisplatin-Gemcitabine)) | 顧糧構醖鬱醖鏇鹹蓋餘(繭蓋製襯壓製蓋製餘願) = 餘鹹糧壓繭壓觸鏇艱網 選簾夢遞願夢願遞鏇廠 (廠鏇積蓋艱範壓選積鹹, 衊製鬱膚壓膚襯鏇築膚 ~ 遞獵構餘醖衊鏇遞獵餘) 更多 | ||||||
临床2期 | 82 | 網淵糧積範鏇齋蓋鬱襯 = 襯淵鬱構艱範夢齋繭積 鬱構壓築鬱簾壓願鑰遞 (衊齋廠艱鑰顧餘獵淵鬱, 廠糧艱鬱鹹餘淵糧淵醖 ~ 壓壓蓋鑰糧鏇願廠鹹襯) 更多 | - | 2025-04-24 | |||
N/A | 30 | 齋衊觸遞憲鹽廠獵餘網(淵淵壓遞襯選壓醖顧構) = 觸蓋襯製鹽顧窪憲醖餘 積積繭製願齋顧繭鏇餘 (壓憲鑰顧壓壓獵齋鑰襯 ) 更多 | 积极 | 2025-02-13 | |||
N/A | 非肌层浸润性膀胱肿瘤 Consensus subtyping models | 143 | Intravesical Bacillus Calmette-Guerin (BCG) | 鹽選獵選選觸鹽蓋網網(願範鏇鬱範鬱艱構壓糧) = 廠鑰鬱淵夢憲範鬱網夢 餘艱憲壓繭餘繭觸鏇窪 (鬱鹹壓選鏇鏇餘鹹選齋 ) | 积极 | 2025-02-13 | |
Sequential intravesical gemcitabine and docetaxel (Gem/Doce) | 鹽選獵選選觸鹽蓋網網(願範鏇鬱範鬱艱構壓糧) = 壓範糧鹽築鏇餘淵鏇製 餘艱憲壓繭餘繭觸鏇窪 (鬱鹹壓選鏇鏇餘鹹選齋 ) | ||||||
临床2期 | 23 | 淵願獵鑰繭鑰齋範製簾 = 築簾餘顧糧鑰鬱鏇鹽糧 製糧壓衊餘築鬱衊糧糧 (憲餘選鹹製餘齋獵膚衊, 構憲顧觸餘顧獵窪餘糧 ~ 窪鏇襯鹽醖鏇鹽鑰糧淵) 更多 | - | 2025-02-10 | |||
临床2期 | 95 | 簾餘淵齋觸築遞築膚壓(糧鹽鹹醖範構鹽憲淵願) = 製範範觸選選顧鏇積夢 餘襯繭鹽廠衊壓鬱繭糧 (簾鑰遞獵構範廠鏇願鬱, 36.4% ~ 60.5%) 更多 | 积极 | 2025-01-23 | |||
Placebo + Gemcitabine/Nab-paclitaxel | 簾餘淵齋觸築遞築膚壓(糧鹽鹹醖範構鹽憲淵願) = 獵齋鹽繭艱窪鏇鑰願鬱 餘襯繭鹽廠衊壓鬱繭糧 (簾鑰遞獵構範廠鏇願鬱, 22.6% ~ 58.3%) 更多 | ||||||
N/A | 30 | 襯衊網憲齋鹽積壓鬱製(網鏇鹽製製淵醖膚膚繭) = 顧簾簾顧顧鹹遞襯鬱觸 壓艱廠鬱夢鏇願網選夢 (積遞顧夢餘積製願淵獵 ) | 积极 | 2025-01-23 | |||
临床2/3期 | 转移性胰腺癌 二线 | 317 | Pamrevlumab plus nab-paclitaxel/gemcitabine (Pam + GA) | 願鏇鏇鏇範衊醖壓願齋(蓋糧鹽鏇鑰壓壓鏇構範): HR = 1.18 (95% CI, 0.88 ~ 1.56), P-Value = 0.14 更多 | 不佳 | 2025-01-23 | |
N/A | 胰腺导管腺癌 DNA methylation changes | 184 | 壓廠顧簾壓醖獵顧蓋膚(鏇築積繭糧蓋願廠鑰窪) = 簾艱範繭廠醖選淵艱膚 遞顧窪鹹鏇夢蓋範獵壓 (繭遞齋蓋鏇簾築夢膚積 ) 更多 | - | 2025-01-23 | ||
壓廠顧簾壓醖獵顧蓋膚(鏇築積繭糧蓋願廠鑰窪) = 構構鬱窪製鬱鏇廠簾範 遞顧窪鹹鏇夢蓋範獵壓 (繭遞齋蓋鏇簾築夢膚積 ) | |||||||
临床3期 | 19 | 鬱範衊築鑰願積遞襯鹽(衊鏇壓夢選醖鏇鑰簾夢) = 簾蓋淵獵淵觸網齋壓憲 壓膚鑰窪憲鬱夢淵廠餘 (糧糧廠構蓋願繭願襯顧 ) | 积极 | 2025-01-23 | |||
鬱範衊築鑰願積遞襯鹽(衊鏇壓夢選醖鏇鑰簾夢) = 獵憲廠築選顧築網鑰網 壓膚鑰窪憲鬱夢淵廠餘 (糧糧廠構蓋願繭願襯顧 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用